Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04477200 · ClinicalTrials.gov registry record · Phase 1
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
A Phase 1 study of Recurrent Glioblastoma and Recurrent Gliosarcoma, sponsored by University of Michigan Rogel Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT04477200: Active Phase 1 study of Recurrent Glioblastoma and Recurrent Gliosarcoma, sponsored by University of Michigan Rogel Cancer Center.
NCT04477200 is a Phase 1 study of Recurrent Glioblastoma and Recurrent Gliosarcoma that is active but no longer recruiting, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 68 participants, roughly in line with the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04477200, a Phase 1 study of Recurrent Glioblastoma and Recurrent Gliosarcoma, is active but no longer recruiting, sponsored by University of Michigan Rogel Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.
Primary Outcome
The concentration of MPA (the active metabolite of mycophenolate mofetil \[MMF\]) in tumor tissue, measured by mass spectrometry on a continuous scale after one week of MMF administration. This measure includes all phase 0 participants.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Temozolomide
- DRUG Mycophenolate Mofetil
- PROCEDURE Re-resection (as part of standard of care)
Study Locations (1)
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2020-08-05 |
| Est. Completion | 2027-11-05 |
| Phase | Phase 1 |
What the registry record for NCT04477200 still lists
NCT04477200 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, roughly in line with the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target.
The record links to 6 conditions, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which Radiation Therapy is the first listed.
NCT04477200 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04477200 about?
NCT04477200 is a clinical study titled "Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma". This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.
What is the current status of trial NCT04477200?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2020-08-05. Estimated completion is 2027-11-05.
What conditions does trial NCT04477200 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma, Recurrent Gliosarcoma, Newly Diagnosed Glioblastoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Gliosarcoma.
What interventions are being tested in trial NCT04477200?
The interventions under investigation include: Radiation Therapy (RADIATION), Temozolomide (DRUG), Mycophenolate Mofetil (DRUG), Re-resection (as part of standard of care) (PROCEDURE).
Who is sponsoring clinical trial NCT04477200?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04477200 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04477200's enrollment target sits among peer trials
68 16th of 62 higher than 47 of 62 other Recurrent Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
RECRUITING · Phase 1
-
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
RECRUITING · Phase 1
-
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
RECRUITING · Phase 1
-
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI